checkpoint inhibitor/bispecific antibody combo: regn2810 and regn1979 in b-lymphoid malignancies
Published 6 years ago • 186 plays • Length 1:13Download video MP4
Download video MP3
Similar videos
-
1:48
the potential of bispecific antibody-containing combinations in patients with b-cell lymphomas
-
2:07
immune checkpoint inhibitors, the next generation cancer therapy - creative biolabs
-
1:51
checkpoint inhibition in the treatment of mpns
-
2:36
a cd38-targeting bispecific antibody in the treatment of r/r t-all
-
1:03
using bispecific antibodies instead of chemotherapy to reach pre-transplant remission in b-all
-
1:53
toxicities and new immune checkpoint inhibitors
-
4:55
checkpoint inhibitor combination approaches for aml/mds: an update
-
2:05
checkpoint inhibitors: parallel management of the disease and immune-related toxicities
-
1:33
sitc clinical practice guidelines on immune checkpoint inhibitor-related adverse events
-
4:15
bispecific antibodies in multiple myeloma: teclistamab, talquetamab, and cevostamab
-
4:58
overview of the toxicities associated with bispecific agents in multiple myeloma
-
0:47
advice for physicians when managing bispecific antibody treatment for patients with myeloma
-
0:55
the significance of cr as an endpoint in frail patients with multiple myeloma
-
1:21
cd20/cd3 bispecific antibodies in r/r dlbcl: glofitamab and epcoritamab
-
1:11
long-term safety analysis of pirtobrutinib in r/r b-cell malignancies
-
3:21
nox2: a potential immune checkpoint for inhibition in aml
-
2:15
cd47-blocking checkpoint inhibitor tti-621 shows promising results for cutaneous t-cell lymphomas
-
1:22
managing cytopenias following jak inhibitor treatment & achieving true disease modification in mf
-
3:27
the mechanism of bispecific t-cell engagers in b-all: genomic alterations